MarkEBorowskyMD

Obstetrics & Gynecology • Neptune, NJ

General Gynecology, Gynecologic Oncology

Physician

Join to view full profile

Dr. Borowsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Borowsky's full profile

Already have an account?

Office
Jersey Shore University Medical Center, Gynecologic Oncology
19 Davis Ave., Hope Tower, E7129
Neptune, NJ 07753
Phone+1 732-897-7944

Fax+1 732-922-8264
Is this information wrong?

Education & Training

SUNY Health Science Center at BrooklynFellowship, Gynecologic Oncology, 2001 - 2004
Zucker School of Medicine at Hofstra/NorthwellResidency, Obstetrics and Gynecology, 1993 - 1997
Perelman School of Medicine at the University of PennsylvaniaClass of 1993

Certifications & Licensure

NJ State Medical License 2005 - 2025
DE State Medical License 1997 - 2021
PA State Medical License 2004 - 2008
NY State Medical License 1995 - 2006
IL State Medical License 2004 - 2005
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Philadelphia Magazine Castle Connolly, 2014-2021
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Fellow (FACS) American College of Surgeons

Clinical Trials

Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20
Completed
Phase 2
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Start of enrollment: 2010 Jul 01
Completed
Phase 2
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Unknown status
Not Applicable
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 2
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
Active, not recruiting
Phase 3
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Start of enrollment: 2010 Jun 07
Completed
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Mar 21
Completed
Phase 2
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Sex cord stromal tumor presenting with hair loss in postmenopausal women.
Connie W Cheng, Karim ElSahwi, Mark E Borowsky, Noelle Aikman, Verda Hicks> ;International Journal of Gynaecology and Obstetrics. 2022 Oct 1
67 citations
NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer
Timothy Nacarelli, Takeshi Fukumoto, Joseph A. Zundell, Nail Fatkhutdinov, Stephanie Jean, Mark G. Cadungog, Mark E. Borowsky, Rugang Zhang> ;Cancer Research. 2020 Feb 15
70 citations
EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.
Sergey Karakashev, Takeshi Fukumoto, Bo Zhao, Jianhuang Lin, Shuai Wu, Nail Fatkhutdinov, Pyoung Hwa Park, Galina Semenova, Stephanie Jean, Mark G. Cadungog, Mark E. B...> ;Cancer Cell. 2020 Feb 10
37 citations
ARID1A promotes genomic stability through protecting telomere cohesion
Bo Zhao, Jianhuang Lin, Lijie Rong, Shuai Wu, Zhong Deng, Nail Fatkhutdinov, Joseph A. Zundell, Takeshi Fukumoto, Qin Liu, Andrew V. Kossenkov, Stephanie Jean, Mark G....> ;Nature Communications. 2019 Sep 6
31 citations
CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer
Bipradeb Singha, Sandra L. Harper, Aaron R. Goldman, Benjamin G. Bitler, Katherine M. Aird, Mark E. Borowsky, Mark G. Cadungog, Qin Liu, Rugang Zhang, Stephanie Jean, ...> ;Scientific Reports. 2018 Oct 3
103 citations
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.
Tom L. Stephen, Kyle K. Payne, Ricardo A. Chaurio, Michael J. Allegrezza, Hengrui Zhu, Jairo Perez-Sanz, Alfredo Perales-Puchalt, Jenny M. Nguyen, Ana E. Vara-Ailor, E...> ;Immunity. 2017 Jan 17
85 citations
Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells
Amelia J. Tesone, Melanie R. Rutkowski, Eva Brencicova, Nikolaos Svoronos, Alfredo Perales-Puchalt, Tom L. Stephen, Michael J. Allegrezza, Kyle K. Payne, Jenny M. Nguy...> ;Cell Reports. 2016 Feb 23
27 citations
Morcellation and the Incidence of Occult Uterine Malignancy: A Dual-Institution Review.
T. Picerno, Megan Wasson, Angel R. Gonzalez Rios, Matthew J. Zuber, Nicholas Taylor, Matthew K. Hoffman, Mark E. Borowsky> ;International Journal of Gynecological Cancer. 2016 Jan 1
Incidence of Endometrial Hyperplasia or Carcinoma at the Time of Endometrial Ablation.
T. Picerno, M. Wasson, Matthew K. Hoffman, Mark E. Borowsky> ;Journal of Minimally Invasive Gynecology. 2015 Nov 1
2 citations
Case report: Atypical, 'symplastic' leiomyoma recurring as leiomyosarcoma in the vagina.
Elizabeth J. Cooney, Mark E. Borowsky, Cynthia Flynn> ;Gynecologic Oncology Reports. 2015 Nov 1
169 citations
Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer
Joan L. Walker, C. Bethan Powell, Lee-may Chen, Jeanne Carter, Victoria L. Bae Jump, Lynn P. Parker, Mark E. Borowsky, Randall K. Gibb> ;Cancer. 2015 Jul 1
88 citations
Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression.
Tom L. Stephen, Melanie R. Rutkowski, Michael J. Allegrezza, Alfredo Perales-Puchalt, Amelia J. Tesone, Nikolaos Svoronos, Jenny M. Nguyen, Fahmida Sarmin, Mark E. Bor...> ;Immunity. 2014 Sep 18
15 citations
Intraperitoneal chemotherapy in a pregnant woman with ovarian cancer.
Esther R. Smith, Mark E. Borowsky, Vanita Dharan Jain> ;Obstetrics and Gynecology. 2013 Aug 1
3468 citations
Integrated genomic characterization of endometrial carcinoma
Gad Getz, Stacey Gabriel, Kristian Cibulskis, Eric S. Lander, Andrey Sivachenko, Carrie Sougnez, Michael S. Lawrence, Cyriac Kandoth, David J. Dooling, Robert S. Fulto...> ;Nature. 2013 May 2
7 citations
Port-site metastasis following robotic-assisted radical hysterectomy for squamous cell cervical cancer.
Olivia Bolles, Mark E. Borowsky> ;Gynecologic Oncology Case Reports. 2012 Apr 1
2 citations
Long-term results of maximally aggressive trimodality therapy in a high-risk subset of early-stage cervical cancer patients.
Kevin S. Elliott, Mark E. Borowsky, Edmond S. Malka, Sidney A. Scudder, Gary S. Leiserowitz, Anthony H. Russell> ;The Journal of Reproductive Medicine. 2006 May 1
1 citations
Haymaker gene expression in malignant and normal gynecologic tissues.
Mark E. Borowsky, Ballabh Das, Constantine A. Axiotis, Edmond S. Malka, Ovadia Abulafia, Allen J. Norin> ;The Journal of Histochemistry and Cytochemistry. 2006 Jul 1
2 citations
Malignant thymoma metastatic to the pelvis: A rare case and considerations for management
Kevin S. Elliott, Mark E. Borowsky, Khldoun Bakdounes, Jennifer Huang, Ovadia Abulafia, Yi-Chun Lee> ;Gynecologic Oncology. 2005 Oct 1
4 citations
A retrospective review of 15 years of radical radiotherapy with or without concurrent cisplatin and/or 5-fluorouracil for the treatment of locally advanced cervical ca...
Mark E. Borowsky, Kevin S. Elliott, John C. Pezzullo, Paul Santoso, Walter Choi, Kwang Choi, Ovadia Abulafia> ;Bulletin Du Cancer. 2005 Feb 1
12 citations
Prolonged survival in recurrent endometrial carcinoma to the brain.
Kevin S. Elliott, Mark E. Borowsky, Yi-Chun Lee, Chandrakant Rao, Ovadia Abulafia> ;Gynecologic Oncology. 2004 Oct 1
14 citations
Pericardial effusion, right-sided pleural effusion and ascites associated with stage IV endometriosis. A case report
Michelle Francis, Oluyemi O Badero, Mark E. Borowsky, Yi-Chun Lee, Ovadia Abulafia> ;The Journal of Reproductive Medicine. 2003 Jun 1
Join now to see all